A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
BioNTech SE
BioNTech SE
Evopoint Biosciences Inc.
Beijing Biotech
National Institutes of Health Clinical Center (CC)
858 Therapeutics, Inc.
Radiopharm Theranostics, Ltd
Terremoto Biosciences Inc.
Artios Pharma Ltd
Filamon LTD
PMV Pharmaceuticals, Inc
AstraZeneca
NeoImmuneTech
Qilu Pharmaceutical Co., Ltd.
Children's Oncology Group
A2 Biotherapeutics Inc.
AstraZeneca
M.D. Anderson Cancer Center
Arvinas Inc.
University of Florida
Essen Biotech
Essen Biotech
Revolution Medicines, Inc.
AstraZeneca
Lumicell, Inc.
Perspective Therapeutics
Second Life Therapeutics
Ocellaris Pharma, Inc.
Apollo Therapeutics Ltd
Tanabe Pharma America, Inc.
BicycleTx Limited
Alaunos Therapeutics
Incyte Corporation
Maastricht University Medical Center
Hadassah Medical Organization
Eli Lilly and Company
LigaChem Biosciences, Inc.
Shanghai Escugen Biotechnology Co., Ltd
TCR2 Therapeutics
TCR2 Therapeutics
Palleon Pharmaceuticals, Inc.
Sensei Biotherapeutics, Inc.
Incyte Corporation
Incyte Corporation
Incyte Corporation
Cancer Research UK
Medicenna Therapeutics, Inc.
NGM Biopharmaceuticals, Inc
OncoC4, Inc.
Numab Therapeutics AG
Esperas Pharma Inc.